BACKGROUND: Due to the indolent nature of prostate cancer, new prognostic measures are needed to identify patients with life threatening disease. SAM pointed domain-containing Ets transcription factor (SPDEF) has been associated with good prognosis and demonstrates an intimate relationship with the androgen receptor (AR), however its role in prostate cancer progression remains unclear. METHODS: A tissue microarray constructed from cores of 713 consecutive radical prostatectomy specimens were immunohistochemically stained for SPDEF and correlated with progression free and metastatic free survival. In vitro studies assessed growth rate, migration, and sensitivity to bicalutamide to explore mechanisms behind the tissue microarray observations. RESULTS: Patients with high SPDEF demonstrate longer metastases free survival after receiving the standard of care (HR = 9.80, P = 0.006). SPDEF expression corresponded with bicalutamide growth inhibition and apoptosis induction in all cell lines studied. In addition, a feedforward loop of AR-SPEF expression regulation is observed. CONCLUSIONS: SPDEF may be clinically useful to identify patients who will have extended benefits from androgen deprivation therapy. In vitro observations suggest SPDEF mediates initial sensitivity to androgen deprivation therapy through both AR regulation and downstream events.
BACKGROUND: Due to the indolent nature of prostate cancer, new prognostic measures are needed to identify patients with life threatening disease. SAM pointed domain-containing Ets transcription factor (SPDEF) has been associated with good prognosis and demonstrates an intimate relationship with the androgen receptor (AR), however its role in prostate cancer progression remains unclear. METHODS: A tissue microarray constructed from cores of 713 consecutive radical prostatectomy specimens were immunohistochemically stained for SPDEF and correlated with progression free and metastatic free survival. In vitro studies assessed growth rate, migration, and sensitivity to bicalutamide to explore mechanisms behind the tissue microarray observations. RESULTS:Patients with high SPDEF demonstrate longer metastases free survival after receiving the standard of care (HR = 9.80, P = 0.006). SPDEF expression corresponded with bicalutamide growth inhibition and apoptosis induction in all cell lines studied. In addition, a feedforward loop of AR-SPEF expression regulation is observed. CONCLUSIONS:SPDEF may be clinically useful to identify patients who will have extended benefits from androgen deprivation therapy. In vitro observations suggest SPDEF mediates initial sensitivity to androgen deprivation therapy through both AR regulation and downstream events.
Authors: David P Turner; Victoria J Findlay; Omar Moussa; Victor I Semenchenko; Patricia M Watson; Amanda C LaRue; Mohamed M Desouki; Mostafa Fraig; Dennis K Watson Journal: Prostate Date: 2011-03-28 Impact factor: 4.104
Authors: James L Mohler; Mark A Titus; Suxia Bai; Brian J Kennerley; Fred B Lih; Kenneth B Tomer; Elizabeth M Wilson Journal: Cancer Res Date: 2011-02-08 Impact factor: 12.701
Authors: Jeremy S Schaefer; Yamini Sabherwal; Heidi Y Shi; Venkataraman Sriraman; JoAnne Richards; Alex Minella; David P Turner; Dennis K Watson; Ming Zhang Journal: J Biol Chem Date: 2010-02-05 Impact factor: 5.157
Authors: Qianben Wang; Wei Li; Yong Zhang; Xin Yuan; Kexin Xu; Jindan Yu; Zhong Chen; Rameen Beroukhim; Hongyun Wang; Mathieu Lupien; Tao Wu; Meredith M Regan; Clifford A Meyer; Jason S Carroll; Arjun Kumar Manrai; Olli A Jänne; Steven P Balk; Rohit Mehra; Bo Han; Arul M Chinnaiyan; Mark A Rubin; Lawrence True; Michelangelo Fiorentino; Christopher Fiore; Massimo Loda; Philip W Kantoff; X Shirley Liu; Myles Brown Journal: Cell Date: 2009-07-23 Impact factor: 41.582
Authors: Catherine M Tangen; James R Faulkner; E David Crawford; Ian M Thompson; Daisaku Hirano; Mario Eisenberger; Maha Hussain Journal: Clin Prostate Cancer Date: 2003-06
Authors: M J Donovan; M Noerholm; S Bentink; S Belzer; J Skog; V O'Neill; J S Cochran; G A Brown Journal: Prostate Cancer Prostatic Dis Date: 2015-09-08 Impact factor: 5.554
Authors: Xin-Hua Cheng; Markaisa Black; Vladimir Ustiyan; Tien Le; Logan Fulford; Anusha Sridharan; Mario Medvedovic; Vladimir V Kalinichenko; Jeffrey A Whitsett; Tanya V Kalin Journal: PLoS Genet Date: 2014-09-25 Impact factor: 5.917
Authors: Nima C Emami; Linda Kachuri; Travis J Meyers; Rajdeep Das; Joshua D Hoffman; Thomas J Hoffmann; Donglei Hu; Jun Shan; Felix Y Feng; Elad Ziv; Stephen K Van Den Eeden; John S Witte Journal: Nat Commun Date: 2019-07-15 Impact factor: 14.919
Authors: Rodrigo E Tamura; Juliano D Paccez; Kristal C Duncan; Mirian G Morale; Fernando M Simabuco; Simon Dillon; Ricardo G Correa; Xuesong Gu; Towia A Libermann; Luiz F Zerbini Journal: Oncotarget Date: 2016-03-22